Why Is Neurocrine Biosciences Stock Trading Lower On Friday?
Neurocrine Biosciences Inc. (NASDAQ:NBIX) reported fourth-quarter adjusted EPS of $1.69, higher than the $1.54 reported a year ago, beating the consensus of $1.56. The company reported sales of $627.7 million compared to $515.
Why Neurocrine Biosciences, Inc.’s (NBIX) Stock Is Down 18.53%
Neurocrine Biosciences, Inc.’s NBIX share price has dipped by 18.53%, which has investors questioning if this is right time to buy.
Neurocrine Biosciences stock falls on revenue miss
Investing.com -- Shares of Neurocrine (NASDAQ: NBIX) Biosciences (NASDAQ: NBIX) tumbled 11% as the company reported revenues that fell short of estimates. Despite reporting a 26% growth in INGREZZA® (valbenazine) net product sales for the full year of 2024 compared to the previous year, the company's guidance for 2025 disappointed investors.
BofA cuts Neurocrine Bio stock target to $179, maintains Buy
Biosciences stock, reducing the price target to $179 from $184, while preserving a Buy rating on the shares. Currently trading at $150.51, the company maintains a GREAT financial health score according to InvestingPro analysis,
Which Is a Better Investment, Biogen Inc. or Neurocrine Biosciences, Inc. Stock?
Learn more about whether Biogen Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
Neurocrine Biosciences targets $2.5B-$2.6B INGREZZA sales for 2025 amid expanded sales force
Q4 2024 Management View CEO Kyle Gano highlighted Neurocrine's transformation into a fully integrated biopharmaceutical company. He emphasized the strong performance of INGREZZA, which is poised for double-digit year-over-year growth despite moderated expectations compared to 2024,
Hosted on MSN24m
Neurocrine Biosciences’ Earnings Call: Record Sales & Strategic Growth
Neurocrine Biosciences (($NBIX)) has held its Q4 earnings call. Read on for the main highlights of the call. Neurocrine Biosciences’ earnings call ...
These Stocks Are Moving the Most Today: Amazon, Affirm, Pinterest, Take-Two, Bill Holdings, e.l.f. Beauty, Neurocrine Biosciences, and More
Amazon falls after guidance disappoints and cloud-computing growth misses estimates, Affirm jumps after fiscal second-quarter ...
Q4 2024 Neurocrine Biosciences Inc Earnings Call
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/104.D7q0jHs_.js ...
Neurocrine price target lowered to $185 from $190 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Neurocrine (NBIX) to $185 from $190 and keeps a Buy rating on the shares. FY25 Ingrezza ...
Neurocrine Biosciences Q4 Earnings Preview: What To Expect After The New Drug Approval
Neurocrine's pipeline includes 12 clinical programs, with two Phase 3 trials due to report in 2025. See why I rate NBIX stock ...